Why Regeneron Shares Are Rising Today

Regeneron Pharmaceuticals Inc REGN is trading higher Thursday after the company announced better-than-expected third-quarter financial results.

Regeneron reported quarterly adjusted earnings of $15.37 per share, which beat the estimate of $9.49 per share. The company reported quarterly revenue of $3.45 billion, which beat the estimate of $2.79 billion.

Regeneron expects full-year 2021 non-GAAP R&D to be in a range of $2.55 billion to $2.6 billion.

"We secured a new U.S. government supply agreement and are delivering an additional 1.4 million doses of REGEN-COV. Our Biologics License Application for REGEN-COV as treatment and prophylaxis was accepted by the FDA for priority review, with a mid-April 2022 action date," said Leonard Schleifer, president and CEO of Regeneron.

Regeneron discovers, develops and commercializes products that fight eye disease, cardiovascular disease, cancer and inflammation.

REGN Price Action: Regeneron has traded as high as $686.62 and as low as $441 over a 52-week period.

The stock was up 2.55% at $668.76 at time of publication.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsLeonard Schleiferwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!